HLA-A and neoplasm: To address this, we repeated the above analysis focusing on those mutations that were most likely to be immunogenic by several criteria, including (1) the expression of the gene in the tumor bearing the mutation was above the median expression level of that same gene in all tumors, (2) HLA-A expression in the tumor bearing the mutation was above the median expression of HLA-A in all tumors, and (3) the predicted autologous HLA-A binding affinity of the best scoring peptide containing a given mutation had an IC50 value of 500 nM or less.